Affiliation: Eli Lilly and Company
- Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasmaJialin Mao
Department of Drug Disposition, Eli Lilly and Co Lilly Corporate Center, Indianapolis, IN 46285, USA
Drug Metab Dispos 39:591-602. 2011..Thus, HHSHP produced accurate DDI predictions with a simple IC(50) determined at a single incubation time regardless of the inhibition mechanism; further if needed, the mechanism(s) of inhibition can be identified...
- Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditionsJialin Mao
Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
Drug Metab Dispos 40:706-16. 2012..In conclusion, the HHSHP system proved to be a simple, accurate predictor of DDIs for three major P450s and superior to the protein-free approach...
- Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazoleBing Han
Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
Drug Metab Dispos 41:1329-38. 2013..Model 2 is not recommended for inferring optimal study design and estimation of fraction metabolized by CYP3A...